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We appreciate the interest expressed
by Kubisa, Grodzki, and Wo´jcik in
our recently published study concern-
ing silver nitrate technique for the
management of small bronchopleural
fistulas.1 We are glad to learn that
other colleagues as well have experi-
ence with this method.
As we noted twice in our study,
although this technique was described
once, 25 years ago,2 nothing has been
reported since on the subject, and it is
certain that younger generations of
pulmonologists and thoracic surgeons
alike are not acquainted with it. In an
extensive review on the endoscopic
management of bronchopleural
fistulas published recently as well,
nothing more than the above was
reported.3
The references mentioned by
Kubisa, Grodzki, and Wo´jcik were
all published during the 1950s and
1960s, before the advent of the flexible
bronchoscope, and referred mainly to
complications of endobronchial tuber-
culosis, which is a completely differ-
ent situation (and topic), ideally rare
nowadays.
To our knowledge, based on a sys-
tematic research of the literature, our
report is the first in the modern era to
present this safe and effective tech-
nique for endoscopic management of
such a serious and difficult-to-treat
complication.
With regard to complications and
safety, we have already described
possible casualties in our report,1
and we are currently working on de-
veloping a new bronchoscopic silver
nitrate applicator for safer and simpler
use with modern flexible broncho-
scopes.
We totally agree that much work
has to be done in the domains of pre-806 The Journal of Thoracic and Cvention and new techniques. How-
ever, we also believe that revisiting
old ideas and techniques (if they are
forgotten and continue to be valid) is
important and can be of considerable
help for clinicians in their daily
practice.
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INDUCTION
RADIOCHEMOTHERAPY: IS IT
TIME FOR A META-ANALYSIS?
To the Editor:
The discussion regarding the safety
and feasibility of pneumonectomy for
non–small cell lung cancer after induc-
tion chemoradiotherapy (IT) is a long-
standing, widely debated issue, in
particular, in the past 2 decades.
We read with great interest the re-
view from Krasna,1 in which pneumo-
nectomy after IT is finally judged as
a risky procedure (especially if right-
sided) that, until further validation
(via prospectically gathered data),ardiovascular Surgery c March 2010should be ‘‘used with caution in expe-
rienced centers.’’
We wish to express our viewpoint
and ask the authors about their opinion
on the basis of our own long-term expe-
rience with IT,2 our recently reported
results on pneumonectomy after IT,3
and in the light of other recently
published authoritative reports.4,5 In
particular, we have evaluated the out-
come-related data of 85 (49 after IT)
consecutive standard pneumonecto-
mies in a 14-year period. Operative
mortality and morbidity do not seem
to be directly associated with IT;
besides, among the clinical, surgical,
and pathologic features, the right-sided
pneumonectomy showed a worse
long-term survival in the overall popu-
lation regardless of the prior application
of IT. Substantially, the same old ques-
tions still stay unanswered: Is pneumo-
nectomy a feasible and safe procedure
after IT? Are there criteria to stratify
the correlated risk after IT-pneumonec-
tomy? Do long-term oncologic results
justify this treatment?
On top of this, it is impossible not to
consider that a complete resection
(thus including the pneumonectomy
option) must be attempted if a radical
chance of cure is sought and the condi-
tions for resectability are met or re-met
after IT.
Still, the indication for pneumonec-
tomy after IT is not yet strictly evi-
dence-based, and a prospective
approach is difficult to imagine given
the substantial impossibility to design
a trial with a proper control group: rad-
ical resection in NSCLC, in fact, has
no ethical comparator alternative. As
well, when the concept of ‘‘experi-
enced center’’ is analyzed, the criteria
to define it are in doubt? If present,
are these criteria validated? What is
the referral benchmark of this valida-
tion: survival or mortality/morbidity?
What is the correct (ethical) approach
to the information given to the patient
when a pneumonectomy is offered af-
ter an IT?
In our opinion, in reality, the ‘‘expe-
rienced centers’’ are those in which the
